Terms: = Ovarian cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Prognosis
21 results:
1. [The expression and significance of protease activated receptor 2 in ovarian epithelial carcinoma].
Liu SH; Ma YM; Zhang YN; Zhao XH; Wang HY; Li B
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):64-73. PubMed ID: 36709122
[No Abstract] [Full Text] [Related]
2. Is increased chronological age a contraindication to debulking surgery for elderly patients with advanced ovarian cancer?
Park SJ; Mun J; Yim GW; Lee M; Chung HH; Kim JW; Park NH; Song YS; Kim HS
J Obstet Gynaecol; 2022 Oct; 42(7):3254-3259. PubMed ID: 36000804
[TBL] [Abstract] [Full Text] [Related]
3. The Immunological Role of CDK4/6 and Potential Mechanism Exploration in ovarian cancer.
Liu C; Huang Y; Cui Y; Zhou J; Qin X; Zhang L; Li X; Li Y; Guo E; Yang B; Li X; Fan J; Li X; Fu Y; Liu S; Hu D; Xiao R; Wang Z; Dou Y; Wang W; Li W; Yang X; Liu J; Peng W; Qin T; You L; Lu F; Sun C
Front Immunol; 2021; 12():799171. PubMed ID: 35095879
[TBL] [Abstract] [Full Text] [Related]
4. Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein birc3.
Hu X; Meng Y; Xu L; Qiu L; Wei M; Su D; Qi X; Wang Z; Yang S; Liu C; Han J
Cell Death Dis; 2019 Feb; 10(2):104. PubMed ID: 30718461
[TBL] [Abstract] [Full Text] [Related]
5. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
Rada M; Nallanthighal S; Cha J; Ryan K; Sage J; Eldred C; Ullo M; Orsulic S; Cheon DJ
Oncogene; 2018 Aug; 37(35):4809-4820. PubMed ID: 29769618
[TBL] [Abstract] [Full Text] [Related]
6. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-aip1 pathway to kill autologous ovarian cancer stem cells.
Qin W; Xiong Y; Chen J; Huang Y; Liu T
J Cell Mol Med; 2018 Jul; 22(7):3364-3376. PubMed ID: 29566310
[TBL] [Abstract] [Full Text] [Related]
7. S100A7 Regulates ovarian cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract] [Full Text] [Related]
8. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract] [Full Text] [Related]
9. National cancer Database Report of Lymphadenectomy Trends in Endometrial cancer.
Cripe J; Handorf E; Brown J; Jain A; Rubin S; Mantia-Smaldone G
Int J Gynecol Cancer; 2017 Sep; 27(7):1408-1415. PubMed ID: 28525495
[TBL] [Abstract] [Full Text] [Related]
10. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
[TBL] [Abstract] [Full Text] [Related]
11. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
[TBL] [Abstract] [Full Text] [Related]
12. Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in cancer.
Chen WC; Wang CY; Hung YH; Weng TY; Yen MC; Lai MD
PLoS One; 2016; 11(5):e0155660. PubMed ID: 27171439
[TBL] [Abstract] [Full Text] [Related]
13. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.
Chen J; Wang R; Zhang B; Lin X; Wei J; Jia Y; Yin Y; Ye S; Zhu T; Chen G; Yuan Y; Lu W; Li K
Am J Obstet Gynecol; 2016 Oct; 215(4):460.e1-460.e13. PubMed ID: 27133009
[TBL] [Abstract] [Full Text] [Related]
14. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract] [Full Text] [Related]
15. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract] [Full Text] [Related]
16. Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer.
Chao A; Lai CH; Tsai CL; Hsueh S; Hsueh C; Lin CY; Chou HH; Lin YJ; Chen HW; Chang TC; Wang TH
PLoS One; 2013; 8(2):e57084. PubMed ID: 23468915
[TBL] [Abstract] [Full Text] [Related]
17. Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk.
Zhang L; Liu W; Hao Q; Bao L; Wang K
Int J Mol Sci; 2012; 13(4):4009-4020. PubMed ID: 22605962
[TBL] [Abstract] [Full Text] [Related]
18. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.
Schmidt M; Hellwig B; Hammad S; Othman A; Lohr M; Chen Z; Boehm D; Gebhard S; Petry I; Lebrecht A; Cadenas C; Marchan R; Stewart JD; Solbach C; Holmberg L; Edlund K; Kultima HG; Rody A; Berglund A; Lambe M; Isaksson A; Botling J; Karn T; Müller V; Gerhold-Ay A; Cotarelo C; Sebastian M; Kronenwett R; Bojar H; Lehr HA; Sahin U; Koelbl H; Gehrmann M; Micke P; Rahnenführer J; Hengstler JG
Clin Cancer Res; 2012 May; 18(9):2695-703. PubMed ID: 22351685
[TBL] [Abstract] [Full Text] [Related]
19. Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Begum FD; Høgdall E; Christensen IJ; Kjaer SK; Blaakaer J; Christensen L; Høgdall C
Acta Obstet Gynecol Scand; 2010; 89(2):190-8. PubMed ID: 20121334
[TBL] [Abstract] [Full Text] [Related]
20. Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma.
Tammela J; Geisler JP; Eskew PN; Geisler HE
Eur J Gynaecol Oncol; 1998; 19(5):438-40. PubMed ID: 9863906
[TBL] [Abstract] [Full Text] [Related]
[Next]
